Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 19.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 430,665 shares of the company’s stock after buying an additional 68,860 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.68% of Vera Therapeutics worth $18,213,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Holocene Advisors LP increased its stake in Vera Therapeutics by 8.8% in the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock valued at $86,390,000 after buying an additional 158,451 shares during the period. Geode Capital Management LLC increased its stake in Vera Therapeutics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock valued at $44,415,000 after buying an additional 20,223 shares during the period. Jennison Associates LLC increased its stake in Vera Therapeutics by 82.0% in the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock valued at $34,418,000 after buying an additional 366,763 shares during the period. Lord Abbett & CO. LLC increased its stake in Vera Therapeutics by 41.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after buying an additional 124,197 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in Vera Therapeutics by 44.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 171,573 shares of the company’s stock valued at $7,584,000 after buying an additional 52,573 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on VERA shares. Wells Fargo & Company started coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price on the stock. JPMorgan Chase & Co. decreased their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price on the stock. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of “Buy” and an average target price of $64.67.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $27.70 on Thursday. Vera Therapeutics, Inc. has a 52 week low of $25.99 and a 52 week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $32.14 and its 200 day simple moving average is $39.42. The firm has a market capitalization of $1.77 billion, a PE ratio of -10.61 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the transaction, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 21.70% of the stock is owned by insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.